The roles of artificial intelligence (AI) and machine learning (ML) in drug development, from target selection and validation to more efficient clinical trials, continue to increase. Recently launched biotech company Immunai is pairing the technology with cancer immunotherapy in an attempt to tailor treatments and improve patient outcomes.

The human immune system functions beautifully, as long as there is a balance. When certain cells predominate, however, it runs into trouble.

“The whole problem is that there is an imbalance between the various components of the immune system. “This imbalance of the various components can induce diseases such as allergy, autoimmunity and even cancer.” Immunai Chief Science Officer Jacques Banchereau, Ph.D., told BioSpace.